ESMO 2018: TiNivo: Tivozanib Combined With Nivolumab: Safety and Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)

Click Here To View Our ASCO Poster:

TIVO-3: Final OS Analysis Of A Phase III, Randomized, Controlled, Multicenter, Open-Label Study To Compare Tivozanib To Sorafenib In Subjects With Metastatic Renal Cell Carcinoma (RCC)